No abstract

All physical and psychological outcomes improved clinically meaningful in "fit" (non-responding by FTSTS) and unfit patients.Conclusions: Cancer-treatment related fatigue syndrome rehabilitation is both effective in endurance training responders and non-responders fpr psychological and social outcomes. Further research is justified testing different types of interventions tailored to subgroups.Legal entity responsible for the study: The authors.

were associated with improved survival in the patients that did not receive the specific therapy. Furthermore, RT-GS and ChemoRT-GS both had significant interaction terms with treatment on MVA (RT-GS: pZ0.0009; ChemoRT: pZ0.02). Notably, the Chemo-GS had improved performance compared to MGMT promoter methylation (pZ0.097, HRZ0.87 [0.74-1.02]) in chemo treated patients. Conclusion: We successfully developed and validated three transcriptomic signatures that predict benefit from current standard of care adjuvant therapies for GBM. These signatures represent the first molecular predictors for RT and chemo+RT response in GBM that are predictive of treatment response, rather than merely prognostic. Furthermore, Chemo-GS outperforms MGMT promoter methylation, the current clinical gold standard. This novel PDX-driven approach shows promise in being able to model treatment response clinically and may be generalizable to other tumor types. These gene signatures represent a significant advance towards personalizing therapies for patients with GBM, and efforts toward prospective validation are ongoing.

No abstract

No abstract